Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.49 |
| ▸ | CTSS | P25774 | 12/20 | 0.49 |
| ▸ | CTSL | P07711 | 3/20 | 0.48 |
| ▸ | CTSB | P07858 | 3/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2953753 | 0.84 | ATM (0.47) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL12203694 | 0.81 | NPC1 (0.63) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL29401299 | 0.81 | NPC1 (0.63) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL3676166 | 0.81 | NPC1 (0.63) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL3676162 | 0.81 | NPC1 (0.63) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL5586794 | 0.81 | ATM (0.49) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL4276615 | 0.79 | CTSS (0.49) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL3621416 | 0.79 | CTSS (0.49) | CTSKCTSSCTSLCTSBATM | |
| Dimethylamine SCHEMBL1435916 | 0.79 | ATM (0.60) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL825511 | 0.77 | KCNA5 (0.53) | CTSKCTSSATMAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241810-B2 | Formamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | PFIZER LIMITED (GB) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | FH, FAH, HRH4 | CTSK 1325/4885CTSS 823/4885CTSL 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.